Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 18;13(3):214–227. doi: 10.1080/15592294.2016.1229730

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PMC Copyright notice

Figure 7. — SFRP3 mRNA re-expression after in vitro demethylation of adenocarcinoma cell lines A549 and SK-LU-I. (A) Semiquantitative real-time PCR showing SFRP3 mRNA expression without and after treatment with 5-aza-2’-deoxycytidine (DAC) and Trichostatin A (TSA) in the adenocarcinoma cell line A549. Increased SFRP3 mRNA expression is shown as fold-change relative to untreated A549 control cells. (B) and (C) Quantitative SFRP3 exon1 methylation was analyzed by pyrosequencing of six CpG duplets in A549 cells without and after DAC and TSA treatment. Area charts visualize mean methylation for each CpG of untreated, DAC, TSA, and DAC/TSA treated cells. (D) Semi quantitative real-time PCR showing SFRP3 mRNA expression without and after treatment with DAC and TSA in the adenocarcinoma cell line SK-LU-1. Increased SFRP3 mRNA expression is demonstrated as fold-change relative to untreated control cells. (E) and (F) Quantitative SFRP3 exon1 methylation was analyzed by pyrosequencing of six CpG duplets in SK-LU-1 cells without and after treatment with DAC and TSA. Area charts visualize mean methylation for each CpG relative to the respective treatment of SK-LU-1 cells.